Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

Inclusion Criteria

• •Age\> 18 years;
• •Patient with an ovarian malignant germ cell tumor (TGMO) or a stroma tumor and / or sex cords (TSCS) treated optimally;
• •Patient who has had surgery and chemotherapy (interest group) or only a surgery (control group);
• •Patient in remission more than 2 years after the end of the initial treatment;
• •Relapse authorized if remission more than 2 years after the end of the treatment;
• •Patient with no other cancers (with the exception of basal cell skin carcinomas, in situ cancers of the breast and cervix);
• •Patient having signed his consent to participate